BAXTER INTL INC shareholders Q3 2020

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2020
NameSharesValueWeighting ↓
Kavar Capital Partners, LLC 39,912$3,210,0001.08%
Bartlett & Co. LLC 573,019$46,082,0001.08%
Doyle Wealth Management 115,669$9,302,0001.08%
Cubic Asset Management, LLC 37,260$2,996,0001.08%
MASTRAPASQUA ASSET MANAGEMENT INC 94,926$7,634,0001.07%
MEYER HANDELMAN CO 254,061$20,431,0001.04%
Quantamental Technologies LLC 17,384$1,398,0001.03%
CLOUGH CAPITAL PARTNERS L P 177,300$14,258,0001.03%
GUARDIAN CAPITAL ADVISORS LP 81,362$6,512,0001.00%
EVERETT HARRIS & CO /CA/ 634,656$51,039,0001.00%
Adalta Capital Management LLC 16,915$1,364,0001.00%
Integral Health Asset Management, LLC 40,000$3,217,0000.98%
Olstein Capital Management, L.P. 67,000$5,388,0000.98%
ING GROEP NV 289,580$23,288,0000.96%
American Assets Investment Management, LLC 57,829$4,651,0000.96%
CI INVESTMENTS INC. 2,379,062$191,324,0000.95%
CINCINNATI INSURANCE CO 458,000$36,832,0000.94%
DALTON GREINER HARTMAN MAHER & CO 70,347$5,657,0000.92%
Murphy Pohlad Asset Management LLC 20,754$1,669,0000.89%
Ardevora Asset Management LLP 580,736$46,703,0000.86%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2020. To view BAXTER INTL INC's shareholder history, click here.